Cefoxitin

®

MedChemExpress

Cat. No.:	HY-B1825	S
CAS No.:	35607-66-0	O
Molecular Formula:	C ₁₆ H ₁₇ N ₃ O ₇ S ₂	NHH
Molecular Weight:	427.45	S
Target:	Antibiotic; Bacterial	O
Pathway:	Anti-infection	NHH
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)	

SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (233.95 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg	
		1 mM	2.3395 mL	11.6973 mL	23.3945 mL	
		5 mM	0.4679 mL	2.3395 mL	4.6789 mL	
		10 mM	0.2339 mL	1.1697 mL	2.3395 mL	
	Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent o Solubility: ≥ 2.5 m	vent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline 2.5 mg/mL (5.85 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.85 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.85 mM); Clear solution					

BIOLOGICAL ACTIVITY				
Description	Cefoxitin, a β-lactam antibiotic, is a broad-spectrum, second-generation cephalosporin. Cefoxitin has a broad spectrum antibacterial activity which includes anaerobic as well as Gram-positive and Gram-negative aerobic bacteria ^{[1][2]} .			
IC ₅₀ & Target	β-lactam			
In Vitro	Cefoxitin has good activity against Gram-positive bacteria. The MICs for several Gram-positive pathogens are in the range of 1-6 μg/mL ^[1] . Cefoxitin exhibits high efficacy killing B. burgdorferi at concentration of 1.25 μM/mL ^[3] .			

	MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
In Vivo	Cefoxitin (20 mg/kg; i.p.; daily; for 5 days) effectively kills B. burgdorferi in C3H/HeN mice model ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
	Animal Model:	Four-week-old female C3H/HeN mice ^[3]		
	Dosage:	20 mg/kg		
	Administration:	Intraperitoneal injection, daily, for five consecutive days		
	Result:	Had shown high efficacy killing B. burgdorferi in vivo.		

CUSTOMER VALIDATION

- Nat Microbiol. 2023 Mar;8(3):410-423.
- Nat Commun. 2023 Mar 22;14(1):1594.
- Nat Commun. 2022 Mar 2;13(1):1116.
- J Antimicrob Chemother. 2020 Jul 1;75(7):1850-1858.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. E O Stapley, et al. Cefoxitin and cephamycins: microbiological studies. Rev Infect Dis. Jan-Feb 1979;1(1):73-89.

[2]. R N Brogden, et al. Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1979 Jan;17(1):1-37.

[3]. Venkata Raveendra Pothineni, et al. In vitro and in vivo evaluation of cephalosporins for the treatment of Lyme disease. Drug Des Devel Ther. 2018; 12: 2915–2921.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA